JY
CTXR icon

Jeff Yass’s Citius Pharmaceuticals CTXR Stock Holding History

Jeff Yass’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.13K Sell
11,795
-25,043
-68% -$17K ﹤0.01% 13168
2026
Q1 		$33.2K Buy
36,838
+23,940
+186% +$19.3K ﹤0.01% 12743
2025
Q4 		$10K Sell
12,898
-35,288
-73% -$44.1K ﹤0.01% 12058
2025
Q3 		$59.8K Buy
48,186
+33,987
+239% +$47.4K ﹤0.01% 11801
2025
Q2 		$22.6K Buy
+14,199
New +$13K ﹤0.01% 12311
2024
Q4 		– Sell
-6,603
Closed -$44.5K – 12339
2024
Q3 		$82.6K Sell
6,603
-19,019
-74% -$320K ﹤0.01% 11160
2024
Q2 		$374K Buy
25,622
+25,173
+5,606% +$451K ﹤0.01% 8965
2024
Q1 		$10.1K Sell
449
-5,191
-92% -$94.8K ﹤0.01% 11908
2023
Q4 		$107K Buy
5,640
+3,660
+185% +$69.4K ﹤0.01% 11272
2023
Q3 		$33.9K Sell
1,980
-4,029
-67% -$95.8K ﹤0.01% 11442
2023
Q2 		$180K Sell
6,009
-12,371
-67% -$407K ﹤0.01% 10390
2023
Q1 		$538K Buy
18,380
+5,208
+40% +$150K ﹤0.01% 8403
2022
Q4 		$260K Buy
13,172
+10,985
+502% +$300K ﹤0.01% 9451
2022
Q3 		$66K Sell
2,187
-4,848
-69% -$133K ﹤0.01% 12018
2022
Q2 		$162K Buy
7,035
+1,644
+30% +$45.1K ﹤0.01% 10926
2022
Q1 		$241K Sell
5,391
-1,968
-27% -$77.7K ﹤0.01% 10791
2021
Q4 		$283K Sell
7,359
-3,285
-31% -$149K ﹤0.01% 10623
2021
Q3 		$540K Buy
10,644
+2,351
+28% +$118K ﹤0.01% 9179
2021
Q2 		$721K Buy
8,293
+4,370
+111% +$263K ﹤0.01% 8670
2021
Q1 		$175K Buy
+3,923
New +$156K ﹤0.01% 11532
2020
Q1 		– Sell
-971
Closed -$25K – 10303
2019
Q4 		$25K Buy
+971
New +$14.2K ﹤0.01% 9462

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM

Jeff Yass's CTXR Position: Q2 2026 in Review

Jeff Yass reduced its Citius Pharmaceuticals (CTXR) stake by 68% in Q2 2026, selling an estimated $17K and leaving 11,795 shares worth $7.13K. The position accounts for ﹤0.01% of the portfolio, ranked #13168.

Jeff Yass first reported a position in CTXR in Q4 2019 and has held it in 21 quarters since. The position peaked at $721K in Q2 2021. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • Jeff Yass held 11,795 shares of Citius Pharmaceuticals worth $7.13K as of Q2 2026.
  • Jeff Yass sold 25,043 Citius Pharmaceuticals shares in Q2 2026, an estimated $17K.
  • Citius Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #13168 holding.
  • Jeff Yass first reported a position in Citius Pharmaceuticals in Q4 2019 and has held it in 21 quarters since.
  • Jeff Yass's Citius Pharmaceuticals position peaked at $721K in Q2 2021.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.